@article{1ee290b151af4f9f8f1405a93225f43e,
title = "Proceedings: Pathways for successful translation of new imaging agents and modalities—phase III studies",
author = "Gambhir, \{Sanjiv S.\} and Shankar, \{Lalitha K.\} and Eben Rosenthal and Warram, \{Jason M.\} and Munir Ghesani and Hope, \{Thomas A.\} and Jacobs, \{Paula M.\} and Jacobson, \{Gunilla B.\} and Terri Wilson and Siegel, \{Barry A.\}",
note = "Funding Information: Thomas Hope is on the JNM editorial board. Barry A. Siegel is a JNM consulting editor; an advisory board member for Blue Earth Diagnostics and GE Healthcare; and a consultant for Avid Radiopharmaceuticals, Inc., BTG Management Services, Capella Imaging, LLC, Curium Pharma, ImaginAb, Inc., Merrimack Pharmaceuticals, Inc., and Progenics Pharmaceuticals, Inc. He also receives clinical trial support from Blue Earth Diagnostics and Progenics Pharmaceuticals, Inc. Sanjiv S. Gambhir has active imaging grants from Sanofi-Aventis, US, Inc., Biogen Inc., Novocure, Philips Medical, and Pliant Therapeutics, Inc. He is a cofounder of CellSight Technologies, Endra Life Sciences, and Earli Inc. He is on the advisory boards of Centella Therapeutics, Inc., Click Diagnostics, Verily, ImaginAb, MagArray Inc., Konica-Minolta Inc., Vave Inc., Nines Inc., NinePoint Medical, GE Healthcare (ad hoc), Alpha Source Inc., RefleXion Medical, Spectrum Dynamics, Vor Biopharma, TauMark Inc., Piramal MI, Life Molecular Imaging, Infinitus Inc., NuvOx Inc., Bracco Inc., Grail Inc., and VisualSonics/Fuji Inc. No other potential conflict of interest relevant to this article was reported.",
year = "2019",
month = jun,
doi = "10.2967/jnumed.118.219824",
language = "English",
volume = "60",
pages = "736--744",
journal = "Journal of Nuclear Medicine",
issn = "0161-5505",
number = "6",
}